Karvy Stock Broking Limited has maintained ‘Buy’ rating on Reliance Industries stock to achieve a target of Rs 1200-1220 within 1-2 days.

According to Karvy, day traders can buy the stock below Rs 1150 with a stop loss of Rs 1125.

Shares of the company, on Monday (Mar 09), closed at Rs 1153.85 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 99.41 and 11.92 respectively. The share price has seen a 52-week high of Rs 2706 and a low of Rs 930 on BSE.

Karvy Stock Broking Limited has maintained ‘Buy’ rating on Maruti Suzuki stock to achieve a target of Rs 685 within 2-3 sessions.

According to Karvy, day traders can buy the stock between Rs 650-655 with a stop loss of Rs 640.

Shares of the company, on Thursday (Mar 05), closed at Rs 667.60 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 44.38 and 14.42 respectively. The share price has seen a 52-week high of Rs 945.55 and a low of Rs 428.40 on BSE.

Karvy Stock Broking Limited has maintained ‘buy’ rating on Lanco Infratech stock with an intraday target of Rs 121.50.

According to Karvy, interested traders can purchase the stock between Rs 114-116 with a strict stop loss of Rs 110. If the stock market remains on positive track, the stock pricing becomes more attractive, and reach above Rs 123.
 
Shares of the company, on Wednesday (March 05), closed at Rs 114.15 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 11.49 and 10.23 respectively. The share price has seen a 52-week high of Rs 589 and a low of Rs 83.10 on BSE.

Areva T&D India Ltd, the Indian arm of French energy firm Areva SA has signed a contract worth Rs 60 crore for Hybrid Gas-Insulated Substation with Rajasthan Rajya Vidyut Prasaran Nigam Limited (RRVPNL) for Indira Gandhi Nagar substation (Jagatpura) at Jaipur.

A company official said, that this is the first 145 kV hybrid GIS order for AREVA T&D in India and only the second order of its kind in the country.

The announcement by Aurobindo Pharma to enter in to a strategic deal with US-based pharmaceutical major Pfizer helped its shares price on the Bombay Stock Exchange on Wednesday. The deal would allow selling of generic medicines, used for cardiovascular disease and central nervous system disorders, in the US and European market.

The global generic market is currently worth $270 billion and expected to grow over $500 billion in the next five years. Pfizer holds considerable shares in drug market, selling $10 billion non-exclusive drug annually.

Karvy Stock Broking Limited has maintained ‘Buy’ rating on Grasim stock to achieve a target of Rs 1450 within 2-3 days.

According to Karvy, day traders can buy the stock between Rs 1350-1360 with a stop loss of Rs 1300.

Shares of the company, on Tuesday (Mar 03), closed at Rs 1362.05 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 210.60 and 6.57 respectively. The share price has seen a 52-week high of Rs 2930 and a low of Rs 831 on BSE.